ANDA 77009, held by Taro. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77009 (Ondansetron Hydrochloride), held by Taro, was first approved by FDA on Nov 30, 2007, with 6 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 30, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 4MG BASE/5ML · solution;oral | Ondansetron Hydrochloride | Discontinued |
| Apr 23, 2018 | Supplement 11Labeling · Standard review | Approved | None posted |
| Mar 30, 2017 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 20, 2014 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 20, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 27, 2012 | Supplement 4Labeling | Approved | None posted |
| Apr 29, 2011 | Supplement 3Labeling | Approved | None posted |
| Nov 30, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters